Pictogram of Biolimus A9 drugProven efficacy
of the Biolimus A9™ drug

Very low restenosis rate in bifurcation lesions





Low in-stent late loss in DIVERGE at 9 months2





Highest lipophilicity of the common limus drugs5
  • Minimizes systemic exposure and reduces the drug circulating in the bloodstream
  • Due to high lipophilicity, the drug is rapidly absorbed by tissue

2. Verheye, S. et al., “9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions. The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study”, J Am Coll Cardio 2009;53:1031–9
4. Verheye S., “Devax AXXESS™ Special Utility of Self Expanding Nitinol Stent For Bifurcation Lesions”, oral presentation, TCT 2009
5. Data on le at Biosensors Intl


CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology and endovascular products, including BioMimics 3D™, BioMatrix Flex™, BioMatrix Flex™BTK, BioMatrix NeoFlex™, BioMatrix™, Axxess™, BioFreedom™, Chroma™, BioStream™, BioPath™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. All other trademarks are the property of their respective owners.

BioMatrix Flex, BioMatrix Flex BTK, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. BioMimics 3D and other cited trademarks are the property of their respective owners.